Bromocriptine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Bromocriptine
- Bromocriptine: From Parkinson Disease to Congenital Disorder of Glycosylation with Defective Fucosylation
Bromocriptine: From Parkinson Disease to Congenital Disorder of Glycosylation with Defective Fucosylation
One-Sentence Summary
Bromocriptine is a dopamine receptor agonist, originally used for Parkinson disease, hyperprolactinaemia and acromegaly. The TxGNN model predicts it may be effective for congenital disorder of glycosylation with defective fucosylation, but no clinical trials and no publications currently support this prediction. It is a computational prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson disease, hyperprolactinaemia, acromegaly (from the knowledge graph; the Singapore licence record contains no indication text) |
| Predicted New Indication | Congenital disorder of glycosylation with defective fucosylation |
| TxGNN Prediction Score | 99.83% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, bromocriptine is a dopamine D2-family receptor agonist. Its efficacy in Parkinson disease and prolactin-related disorders is established.
No mechanistic link to fucosylation pathways has been identified in the data compiled for this report. The high TxGNN score is a computational output only and should not be read as biological or clinical support. The disease is a rare congenital metabolic disorder, and dopamine receptor agonism has no evident connection to the defective fucosylation underlying it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN09036P | AA PHARMA BROMOCRIPTINE TABLET 2.5 mg (Apotex Inc) | Film-coated tablet | Not stated in the licence record |
Safety Considerations
- Contraindications (from knowledge-graph associations, not package insert text): hypertensive disorders (including hypertension), pre-eclampsia (mild and severe) and HELLP syndrome, liver disease, gallbladder disease, coronary artery disease, and stroke or cerebrovascular disorders (including cerebral infarction).
- Drug Interactions: 87 interactions were identified. Those listed include:
- Major: isometheptene, lorcaserin.
- Moderate (examples): clarithromycin, metoclopramide, promethazine, morphine, opium, ethanol, lansoprazole, deferasirox, dronabinol, nabilone, nitisinone.
For official warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no clinical trials, no literature and no identifiable mechanistic link between dopamine agonism and defective fucosylation. The evidence is not sufficient to justify further investment at this time.
To proceed, the following is needed:
- A biological rationale linking bromocriptine's mechanism to fucosylation pathways, together with detailed mechanism of action data
- Preclinical studies in relevant disease models
- The official package insert warnings and contraindications from HSA
- Review of the other ranked predictions, since some have more supporting data. For example, retinal dystrophy has indirect preclinical and case-level evidence, and schizophrenia has one small Phase 4 trial focused on metabolic effects. Bromocriptine-induced psychosis has also been reported, so that direction carries a safety concern.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.